Added to YB: 2025-11-05
Pitch date: 2025-10-31
PRTA [neutral]
Prothena Corporation plc
-7.3%
current return
Author Info
BiotechBonanza shares takes on biotech with a heavy focus on special situations. Sign up for the newsletter.
Company Info
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
Market Cap
$534.5M
Pitch Price
$10.76
Price Target
16.00 (+54%)
Dividend
N/A
EV/EBITDA
-0.97
P/E
-1.91
EV/Sales
18.05
Sector
Biotechnology
Category
growth
PRTA: General update, a closer look at their assets and valuation
PRTA (update): Biotech w/ BMS collab assets PRX005 (Ph2 AD readout 2027) & PRX019 (opt-in decision 2026 for $55M); Roche's Prasinezumab Ph3 enrolling 900 patients (readout 2029); Novo's Coramitug presenting Ph2 data Nov 10. $16 price target. High optionality but long timelines to catalysts.
Read full article (13 min)